Scope and Segmentation

Key Questions this Study will Answer

Key Takeaways

Market Snapshot

Market Snapshot (continued)

8 Big Market Themes for Checkpoint Inhibitors

A Vibrant Ecosystem

Paradigm Expansion to Solid Tumor Cancer Therapies

Regional Launch Highlights

Game-changing Companies

Significant Investor Funding

Key 2016 Predictions—Checkpoint Inhibitor Market

Key Methodology and Scope

Checkpoint Inhibitor Drug Classes

Timeline of Checkpoint Product Approvals

Competitive Landscape—Target Segments, Count of Marketed and Pipeline Products

Checkpoint Segmentation by Subtype

Competitive Landscape—Target Product Counts by Phase

Checkpoint Pipelines by Company, Target, and Phase

Checkpoint Pipelines by Company, Target, and Phase (continued)

Checkpoint Pipelines by Company, Target, and Phase (continued)

Checkpoint Pipelines by Company, Target, and Phase (continued)

Checkpoint Target Segmentation

Competitive Landscape—CTLA-4/CAIX/GITR Segment, Products in Development

Competitive Landscape—PD-1/PD-L1 (programmed death 1-receptor)

Competitive Landscape—LAG-3 (lymphocyte activating gene 3)

Competitive Landscape—TIM-3 (T-cell immunoglobin and mucin domain 3)

PD-1 Product Dashboard—Keytruda® (Pembrolizumab): Merck & Co. (Marketed)

PD-1 Product Dashboard—Opdivo® (Nivolumab): Bristol-Myers Squibb/Ono (Marketed)

CTLA-4 Product Dashboard—Yervoy® (ipilimumab): Bristol-Myers Squibb (Marketed)

PD-L1 Product Dashboard—Tecentriq® (Atezolizumab): Roche (Marketed)

Competitive Overview of Established Companies

Checkpoint Inhibitors—PD-1/PD-L1

PD-L1 Product Dashboard—Avelumab (MSB0010718C): Merck KGaA (Phase III)

PD-L1 Product Dashboard—Durvalumab (MEDI-4736): AstraZeneca / MedImmune (Phase III)

Checkpoint Inhibitors—CTLA-4

CTLA-4 Product Dashboard—Tremelimumab (MEDI-1123): AstraZeneca (Phase III)

Immuno-oncology Combination Therapies

Checkpoint Combination Clinical Trials by Indication

Immuno-oncology Checkpoint Phase III Trials to Watch

Immuno-oncology Checkpoint Phase III Trials To Watch (continued)

Disruptive Technologies and Advances in this Field

Market Opportunities

Potential Game-changing Therapies

Overall Environmental Impact Factors

Checkpoint Product Patent Expirations

Biomarker Challenges

Opportunities in this Market—Escalating Drug Costs

Checkpoint Inhibitor Payer Environment

J-Codes, Annual Costs, and US Payers

Reimbursement Pathway—On-label Reimbursement Path

Reimbursement Pathway—Off-Label, Medicare

Reimbursement Pathway—Off-Label, Commercial Payers

Reimbursement Pathway—Off-Label, Commercial Payers (continued)

A Snapshot of Global Drug Price Control Methods

Pitfalls to Avoid

Companies to Watch

Companies to Watch (continued)

Checkpoint Inhibitor Forecast Sales Total—2020 ($20.5B)Actual Sales by Product

Investors Pour in Significant Funds

Checkpoint Milestones

2015 Deal and Financing—CTLA-4 Receptor Gene Therapy

2015 Deal and Financing Summary—PD-1/PD-L1

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—LAG-3

2015 Deal and Financing Summary—LAG-3 (continued)

2015 Deal and Financing Summary—LAG-3 (continued)

2015 Deal and Financing Summary—TIM-3

Key Conclusions

Growth Opportunities in 4 Checkpoint Inhibitor Segments

New Market Opportunities—Checkpoint Inhibitors

The Last Word—3 Big Predictions

Legal Disclaimer

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—LAG-3 Products in Development

Pipeline Analysis—LAG-3 Products in Development (continued)

Pipeline Analysis—LAG-3 Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development

Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)

Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence